Pomalist Insurance Coverage Expanded for 2nd-Line Multiple Myeloma in Korea

Korea BMS Pharmaceutical has announced that beginning June 1, insurance coverage will be expanded for the PVd regimen—a combination of Pomalyst (pomalidomide), bortezomib, and dexamethasone—to include second-line treatment for patients with multiple myeloma.

This expansion follows an amendment to the “Detailed Matters on the Application Standards and Methods of Medical Care Benefits” announced by the Health Insurance Review and Assessment Service. Under these updated guidelines, patients who have failed one or more previous treatments, including lenalidomide, may now receive insurance benefits when using the PVd regimen.

Expanding Access to Earlier Treatment

The shift to second-line coverage is a significant milestone, as the PVd regimen previously received insurance coverage for third-line treatment in January 2017. By moving this option to an earlier stage of care, the domestic treatment landscape for multiple myeloma now includes an additional benefit option combining oral and subcutaneous administration.

Lee Hye-young, CEO of Korea BMS Pharmaceutical, noted that the expansion is meaningful because it allows treatment benefits to be provided at an earlier point in the patient’s journey.

Did You Know? The expansion of insurance coverage for the PVd regimen to second-line treatment comes approximately 10 years after the initial coverage for third-line treatment was established in January 2017.

Evidence from the OPTIMISMM Study

The decision to expand coverage was based on the efficacy and safety profiles demonstrated in the OPTIMISMM study. This large-scale Phase 3 trial involved 559 patients with relapsed or refractory multiple myeloma who had prior experience with lenalidomide, comparing the PVd regimen against the Vd regimen (bortezomib and dexamethasone).

The study found that the median progression-free survival (PFS) for the PVd group was 11.2 months, compared to 7.1 months for the Vd group—an extension of 4.1 months. The PVd regimen significantly reduced the risk of disease progression or death by 39%.

Consistent results were observed across specific patient subgroups. For patients refractory to lenalidomide, the median PFS was 9.53 months for the PVd group versus 5.59 months for the Vd group. For those who relapsed after first-line treatment, the PVd group showed a median PFS of 20.73 months, compared to 11.63 months for the Vd group.

Expert Insight: Samantha Carter observes that transitioning a therapeutic regimen from third-line to second-line coverage typically reflects a shift in the standard of care, potentially allowing patients to access more potent combinations before their options become limited by multiple previous treatment failures.

Regulatory Approvals and Future Outlook

Pomalyst has received approval from the Ministry of Food and Drug Safety for two specific applications: the combination of bortezomib and dexamethasone for patients who have received one or more treatments including lenalidomide, and the combination of dexamethasone for patients who have relapsed or are refractory after at least two treatments including lenalidomide and bortezomib.

Falcon BMS Korea 4.38

Professor Kim Jin-seok of the Department of Hematology at Shinchon Severance Hospital expressed expectation that this insurance application could bring positive changes to the second-line treatment environment for multiple myeloma in Korea.

Looking forward, this expanded access may lead to a broader adoption of PVd therapy in clinical practice, which could potentially alter the sequencing of therapies for relapsed patients.

Frequently Asked Questions

What is the PVd regimen?
PVd is a three-drug combination therapy consisting of Pomalyst (pomalidomide), bortezomib, and dexamethasone used to treat multiple myeloma.

Who is eligible for the expanded insurance coverage starting June 1?
Coverage is available for multiple myeloma patients who have failed one or more previous treatments, which must include lenalidomide.

What were the primary findings of the OPTIMISMM study regarding the PVd regimen?
The study showed that PVd extended median progression-free survival by 4.1 months (11.2 months vs 7.1 months) compared to the Vd regimen and reduced the risk of disease progression or death by 39%.

How do you feel about the impact of expanding insurance coverage for specialized cancer treatments?